FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therap...
America Forever Bytes
Roche · AFBytes
Company
Roche
Recent coverage
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared ...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broa...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broa...